BD revenue rises 5% as portfolio overhaul drives full-year guidance hike

Becton, Dickinson and Company (NYSE:BDX), commonly known as BD, reported steady growth for its fiscal second quarter of 2026, marking its first full period of operations following a transformative structural reset.

The Franklin Lakes-based medical technology giant posted total revenue of $4.714 billion for the quarter ended March 31, 2026, a 5.2% increase on a reported basis and 2.6% growth on a currency-neutral basis.

The results are presented on a continuing operations basis, accounting for the strategic spin-off of the Biosciences and Diagnostics units and the subsequent combination with Waters Corporation assets.

This reorganization has allowed BD to pivot more aggressively toward its high-growth Medical and Interventional segments.

While the company reported a GAAP diluted loss per share of $(0.13), primarily due to one-time charges related to the spin-off and asset integration, its underlying performance remained robust.

Adjusted diluted EPS for the quarter reached $2.90, reflecting strong operational leverage and the initial realization of synergies from the Waters combination.

BD took significant steps during the quarter to optimize its capital structure and return value to shareholders.

The company executed a $2 billion accelerated share repurchase (ASR) program, signaling management's confidence in the long-term value of the newly streamlined organization.

Simultaneously, BD retired $2.1 billion of its outstanding debt, significantly strengthening its balance sheet and reducing future interest obligations.

On the back of the quarter’s operational strength, BD reaffirmed its full-year revenue guidance and raised its expectations for profitability.

The company now expects full-year adjusted diluted EPS to fall between $12.52 and $12.72, up from its previous projection.